Abstract
Ono is involved in the development of novel medicines; the company is
currently focused on the development of new treatments for diseases of the
cardiovascular, respiratory and central nervous systems, as well as
inflammatory and metabolic disorders. This new strategic analysis report
provides a complete and critical review of the company and includes unique and
independent assessments and forecasts of key products.
Ono is a research-based pure-play pharmaceutical company. For nearly three
centuries, Ono has been involved in the development of novel medicines; the
company is currently focused on the development of new treatments for diseases
of the cardiovascular, respiratory and central nervous systems, as well as
inflammatory and metabolic disorders. Ono employs over 2,400 people and is
headquartered in Osaka, Japan.
In March 2007, Ono established its Strategic Alliance business segment in
order to strengthen research capability and expand the R&D pipeline through
strategic alliances. This new corporate entity is the result of integrating
the Drug Research Alliance and the International Business of Development
segments. Strategic Alliance is tasked with aggressively promoting
collaborative research and alliances through the introduction of leading-edge
technologies from bioventure companies. Ono is aiming to enter 10 new
drug-discovery alliances with bioventure companies over the next five years.
Strategic Alliance is also intending to promote alliances with universities
and research institutes both domestically and overseas. Ono targets 20-30
additional alliances with universities within the next five years.
Ono intends to develop new pharmaceuticals in Japan, the US and Europe, with a
strong emphasis on clinical trials overseas. The company has had research
facilities in the US (Ono Pharma USA Inc; Lawrenceville, NJ) and Europe (Ono
Pharma UK Ltd; London, UK) since 1998, and now has five independently
discovered compounds in its pipeline which are being independently developed
overseas.
The marketing division is tasked with enhancing the reputation of Ono' s
pharmaceutical products through workshops and lecture meetings. Ono expects
the National Health Insurance price revision and implementation of various
healthcare cost containment policies may significantly and adversely affect
its business. The company hopes to offset these losses through the launch of
new products and by enhancing the competitiveness of existing products.
This new strategic analysis report Ono: Pipeline · Products ·
Performance · Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. 4D Pharma reports are updated with the latest data on a continuing
basis and the full report is released quarterly. Once a year the report
undergoes a major review in line with the company' s year end. Buyers of the
print/pdf editions will receive the latest version and quarterly updated
reports for a year. Buyers of the web edition receive online access for one
year via an easy-to-use interface with fast navigation and a full text search
facility. All formats are the same price.
Table of Contents
EXECUTIVE SUMARY
- Introduction
- Current Financial Position
- Company Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Key Agreements
- Employees
- Product Performance Forecasts
- Pipeline Analysis
- Conclusions/Outlook
THERAPEUTIC AREA FOCUS
R&D PIPELINE
CARDIOVASCULAR
- Marketed Products
- R&D Projects
- Growth Forecast
RESPIRATORY
- Marketed Products
- R&D Projects
- Growth Forecast
INFLAMATION
- Marketed Products
- R&D Projects
- Growth Forecast
CNS
- Marketed Products
- R&D Projects
- Growth Forecast
METABOLISM
- Marketed Products
- R&D Projects
- Growth Forecast
OTHERS
- Marketed Products
- R&D Projects
- CNS 7056
- Emend
- ONO-4538
- ONO-8539
- RC-1291
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 2 - KEY CORPORATE EVENTS
APPENDIX 3 - KEY AGREMENTS
- Array BioPharma Inc
- BioFocus DPI Plc
- CeNeS Pharmaceuticals Plc
- Dainippon Sumitomo Pharma
- Dong-A Pharmaceuticals Co Ltd
- GlaxoSmithKline
- Kyorin Pharmaceutical Co Ltd
- Locus Pharmaceuticals Inc
- Medarex Inc
- Merck & Co
- Nissan Chemical Industries Ltd
- Novartis
- Recordati
- Sapphire Therapeutics Inc
- Santen Pharmaceutical Co Ltd
- UCB
APPENDIX 4 - IN FRA STRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 5 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 6 - PRODUCT INDEX
医薬品
その他のカテゴリ
FAQ